Disappearing Colorectal Liver Metastases: Do We Really Need a Ghostbuster?

Healthcare (Basel) · 2022 · PMC9602313 · PMID 36292345

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Previous posthoc analysis of patients’ liver conversion rate treated with FOLFOX or FOLFIRI alone or plus cetuximab showed a positive trend from the addition of anti-EGFR in KRAS wild-type selected cohort (60 vs. 32%) as for the CELIM trial [ 7 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.